Annals of Internal Medicine Tip Sheet
Below please find summaries of new articles that will be published in the next issue of Annals of Internal Medicine. The summaries are not intended to substitute for the full articles as a source of information.
Findings contradict previous reports that link efavirenz with an increased risk for depression and suicidal ideation
URLs go live when the embargo lifts
A multinational collaboration of researchers found that efavirenz, the key component of the most commonly used HIV cocktail in the world, was not associated with increased risk for depression or suicide in patients living with HIV in Uganda. These findings conflict with previous reports from the United States and Europe linking efavirenz with adverse psychiatric side effects. The study is published in Annals of Internal Medicine.
People living with HIV require lifelong treatment with an effective, safe, and affordable drug cocktail. Because of its side-effects profile, efavirenz is no longer recommended as upfront therapy in the global north. However, due to its low cost and combination with other medicines into a single, once-daily pill, efavirenz is commonly used in Africa, where more than 25 million people are living with HIV.
Researchers sought to determine whether efavirenz caused serious psychiatric side
Article originally posted at